3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
12
Prostatic Neoplasms
4
Neoplasms
4
Kidney Neoplasms
3
Carcinoma, Hepatocellular
3
Carcinoma
3
Pain
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Medullary
2
von Hippel-Lindau Disease
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Adenocarcinoma, Follicular
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
cabozantinib
×
Clear all
NCT07227402
2026-06-04
LITESPARK-033
Merck Sharp & Dohme LLC
Phase 3
Recruiting
904 enrolled
NCT03755791
2025-12-11
COSMIC-312
Exelixis
Phase 3
Active not recruiting
837 enrolled
14 charts
NCT03937219
2025-09-10
COSMIC-313
Exelixis
Phase 3
Active not recruiting
855 enrolled
12 charts